← Back to Search

[89Zr]Panitumumab Imaging for Head and Neck Cancer

Phase < 1
Recruiting
Led By Suzanne Lapi, PhD
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Planned standard of care surgery with curative intent for squamous cell carcinoma
Age > 18 years
Must not have
Previous HNSCC resection
Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5-9 days prior to surgery
Awards & highlights

Summary

This trial will compare two ways of looking at tumors to see which is more accurate. It is for people with head and neck cancer who are about to have surgery.

Who is the study for?
This trial is for adults over 18 with newly diagnosed head and neck squamous cell carcinoma, scheduled for surgery. Participants must have normal organ function tests, no history of severe heart or liver conditions within the past 6 months, not be pregnant or breastfeeding, and cannot exceed a weight limit due to scanner size.Check my eligibility
What is being tested?
[89Zr]Panitumumab PET/MRI imaging is being tested against standard [18F-FDG] PET/MRI to see if it's better at finding the exact size and location of tumors in patients with head and neck cancer. This study will not affect treatment plans as it's only for imaging purposes.See study design
What are the potential side effects?
Since this trial focuses on imaging rather than treatment, side effects are minimal but may include allergic reactions to panitumumab tracer components or issues related to MRI procedures like discomfort from lying still.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am scheduled for surgery to remove my squamous cell carcinoma.
Select...
I am older than 18 years.
Select...
I am scheduled for surgery for my newly diagnosed head or neck cancer.
Select...
My cancer has not spread to my lymph nodes according to tests.
Select...
My blood, kidney, and liver tests are within normal ranges.
Select...
I have been diagnosed with squamous cell carcinoma in the head or neck.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I had surgery to remove head or neck cancer.
Select...
I have had interstitial pneumonitis or pulmonary fibrosis.
Select...
I am taking medication for heart rhythm problems.
Select...
My kidney function is normal or only mildly impaired.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5-9 days prior to surgery
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5-9 days prior to surgery for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Image Quality

Trial Design

1Treatment groups
Experimental Treatment
Group I: [89Zr]panitumumab-PET/MRI patientsExperimental Treatment1 Intervention
All study patients will receive [89Zr]Panitumumab-PET/MRI imaging.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Head and Neck Squamous Cell Carcinoma (HNSCC) often involve targeting the epidermal growth factor receptor (EGFR). Monoclonal antibodies like cetuximab and panitumumab bind to EGFR on cancer cells, blocking its activation and the downstream signaling pathways that promote tumor growth and survival. This inhibition can reduce tumor proliferation and enhance the effectiveness of other treatments such as radiation and chemotherapy. For HNSCC patients, targeting EGFR is significant because it directly interferes with the cancer's growth mechanisms, potentially improving treatment outcomes and offering a more personalized therapeutic approach.
Molecularly targeted therapies in head and neck cancers.

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor
1,599 Previous Clinical Trials
2,287,906 Total Patients Enrolled
Suzanne Lapi, PhDPrincipal InvestigatorUniversity of Alabama at Birmingham
1 Previous Clinical Trials

Media Library

[89Zr]Panitumumab Tracer Clinical Trial Eligibility Overview. Trial Name: NCT05183048 — Phase < 1
Head and Neck Squamous Cell Carcinoma Research Study Groups: [89Zr]panitumumab-PET/MRI patients
Head and Neck Squamous Cell Carcinoma Clinical Trial 2023: [89Zr]Panitumumab Tracer Highlights & Side Effects. Trial Name: NCT05183048 — Phase < 1
[89Zr]Panitumumab Tracer 2023 Treatment Timeline for Medical Study. Trial Name: NCT05183048 — Phase < 1
~9 spots leftby Mar 2025